INTRODUCTION
• Triple-negative breast cancer (TNBC) represents 10%-20% of invasive breast cancers 1 and has a very poor prognosis. 2 There is a particular unmet need in TNBC, with a lack of clinically established targeted therapies 3 ; chemotherapy is the only option for metastatic TNBC. 4 • To facilitate access to new treatments, it is increasingly important to understand payer evidence needs in addition to regulatory evidence requirements. 5 • Traditionally, payers focus on hard endpoints such as overall survival (OS), and recommendations for reimbursement would ideally be supported by statistically significant improvement in OS. However, this is sometimes difficult due to long follow-up durations and post-study treatment.
OBJECTIVES
• To identify key health technology assessment (HTA) payer requirements and decision drivers/challenges in assessing new agents in TNBC by focusing on historical HTA submissions in metastatic breast cancer (MBC) as a proxy for TNBC (due to a lack of TNBC HTA assessments).
METHODS
• Assessments included for final analysis were original HTA assessments on drugs for treatment of MBC published since 2010.
• Published assessments were identified via Quintiles' HTA Accelerator Database. 6 HTA agencies covered were NICE (UK), G-BA and IQWiG (Germany), HAS (France), PBAC (Australia), pCODR and INESSS (Canada), Aetna (USA), CTAF (USA: California), ZIN (Netherlands), and TLV (Sweden).
• Key agency comments on the evidence in the submission were extracted, and cross-market and treatment analysis conducted to identify key differences or similarities across HTA agency valuations.
RESULTS

Payer decision drivers and evidence critique
• In total, 96 MBC reports from 9 agencies were identified; the primary elimination process showed 57 potentially relevant reports. After the secondary round of selection, 38 HTA reports on 8 drugs were included in the analysis.
• There were 39 recommendations based on 38 HTA assessments (1 HTA was a multiple technology assessment) as follows: negative (n = 11), positive (n = 8), and positive with restrictions (n = 12); ongoing with draft negative recommendation (n = 2); and no recommendation provided (n = 6).
• The 4 key treatments assessed by multiple agencies were trastuzumab/emtansine (Kadcyla), pertuzumab (Perjeta), eribulin (Halaven), and lapatinib (Tyverb/Tykerb).
• Key decision drivers: clinical benefit was a key driver for positive decisions, while lack of cost effectiveness was a key driver for negative decisions (Figure 1a ).
• Key critique on submissions: the most prevalent negative critique on submissions was that model assumptions were not justified or the relative treatment effect was unclear. The most common positive critique was superiority versus standard care/ best supportive care in the primary endpoint (Figure 1b) .
Clinical evidence requirements
• Most assessments were based on clinical evidence from randomized controlled trials (RCTs), with progression-free survival (PFS) and OS as primary (n = 9 vs 2) and secondary (3 vs 10) endpoints, respectively. -All 12 pivotal RCTs mentioned in the HTA reports were 2-armed studies.
• Nine were open-label; HTA agencies commented on the potential of these trials to introduce bias in 10 of 27 assessments that included such a study. Six were placebo-controlled. -Use of an inappropriate comparator in the key RCTs was criticized in 18 of 38 assessments.
• Twenty-five submissions included health-related quality of life (HRQoL) data, of which 20 used the Functional Assessment of Cancer Therapy-Breast HRQoL instrument. 7 • Lack of HRQoL data was criticized as a data gap in 9 assessments. Figure 2 shows a trend toward more positive recommendations with sound tolerability and HRQoL data.
• American Society of Clinical Oncology (ASCO) working groups' guidelines consider significant improvements in median OS and PFS in previously untreated metastatic TNBC of 4.5-6 and 4 months, respectively, as clinically meaningful. 8 • PFS and OS increments and whether they are considered clinically meaningful according to ASCO criteria are shown in Figure 3 . Only 2 of 12 products met ASCO criteria for being clinically meaningful, and there were no conclusive links between magnitude of survival gain and likelihood of a positive HTA decision; although, there was a trend toward favorable decisions for statistically significant OS improvement (Figure 3 ).
• While significant OS improvement is the standard measure of clinical efficacy in MBC trials, most HTA agencies (except those in Germany) appear to accept PFS as a surrogate endpoint, but only if results are clearly linked to HRQoL improvements.
Health economic (HE) evidence requirements
• Twenty-eight of 38 submissions included an HE evaluation.
-Most widely accepted HE models were cost-utility analyses based on a Markov cohort. Model structure and type were generally accepted by HTA agencies, but with a key challenge of validating model inputs and assumptions. -Immature OS data did not seem to significantly affect HTA outcomes as statistical significance appeared more important (Figure 4 ). -Key uncertainties in economic modelling related to validation of OS and PFS models (9 of 28 assessments) and incorporation of safety data (11 of 28). -Unfavorable incremental cost-effectiveness ratios (ICERs) and uncertainty in economic modelling were key drivers of negative decisions. -HTA opinion suggested that treatment switching should be avoided when possible.
Crossover designs may lead to underestimation of OS benefit, and not all agencies accept the statistical adjustments necessary to account for this. -Lack of disutilities related to treatment-related side effects and complications in pharmacoeconomic models was highlighted as a key criticism by agencies that included economic modelling in decision making. -Medical resource utilization was typically not derived from the RCT, but expert opinion and clinical guidelines were common sources, with the data applied being specific to each market. -ICERs reported ranged from €15,352 to €231,296. In 41% of cases, ICERs reported were considered too high by the HTA agency. 
CONCLUSIONS
• Obtaining a positive HTA recommendation for new MBC drugs is challenging.
Well-validated HE models and acceptable ICERs are important factors in obtaining a favorable HTA opinion. -However, model inputs and assumptions need robust validation in order to be accepted by HTA agencies, or they risk negative recommendation.
• Key drivers of positive HTA opinions include significant and clinically meaningful incremental improvements in OS and/or PFS.
• Despite efforts to clarify meaningful survival outcomes in oncology, 5, 8 there is no uniformly agreed HTA standard. For reimbursement evaluation, the ASCO framework defining clinically meaningful outcomes is limited and more elements need to be considered for adequate decision making.
• Obtaining statistically significant and mature OS data is challenging and cannot always be provided. Thus, other outcomes such as strong and adequately measured HRQoL data should be a key factor to determine value. OS data is not mature, median OS not reached. SMR/ASMR denotes Service médical rendu/Amélioration du service médical rendu. SMR reflects the product's medical benefit which in turn determines reimbursement levels, and ASMR is the rating of the level of clinical benefit given when reimbursement is granted. ABC = advanced breast cancer; ASCO = American Society of Clinical Oncology; chemo = chemotherapy; Cons = considerable benefit; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; Inc = incremental; MBC = metastatic breast cancer; MCID = minimal clinically important difference; Mod = SMR moderate; mTNBC = metastatic triple-negative breast cancer; NA = not reached; Non-quant = non-quantifiable benefit; NR = not reported; OS = overall survival; PFS = progression-free survival; subpop = subpopulation; subst = SMR substantial; TPC = treatment of physician's choice; trast = trastuzumab. 
Kadcyla
No comments on maturity of the data
Perjeta
First data cut at 19-month follow-up was not statistically significant. Update at 30-month follow-up was significant; however, it was not mature as median OS has not been reached in the Perjeta arm Uncertainty about long-term benefit due to immaturity of the data Uncertainty about long-term benefit due to immaturity of the data Uncertainty about long-term benefit due to immaturity of the data Halaven OS data is significant and mature
Tyverb
No comments on maturity of the data, but only 1 of 3 agencies recommended use of Tyverb for a specific population due to lack of evidence for clinical benefit In the selected HTA submissions, immature but statistically significant OS data was accepted to prove clinical benefit of a treatment; however, some agencies did critique uncertainty of long-term benefits. HTA = health technology assessment; OS = overall survival; Stat. Sign. = statistically significant.
